VIR 201

Drug Profile

VIR 201

Alternative Names: Co-X-Gene HIV vaccine; VIR201

Latest Information Update: 24 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Virax Holdings
  • Developer Australian National University; Prescient Therapeutics
  • Class AIDS vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 19 Jul 2007 Clinical data added to the adverse events and Viral Infections immunogenicity sections ,,
  • 21 Nov 2006 The US FDA has approved the IND application for a phase II trial of VIR 201 in the US
  • 25 Oct 2006 Virax has filed an IND with the FDA in the United States for HIV Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top